Monitoring the cytogenetic architecture of minimal residual plasma cells indicates therapy-induced clonal selection in multiple myeloma-Reference-Cited by-同舟云学术

Monitoring the cytogenetic architecture of minimal residual plasma cells indicates therapy-induced clonal selection in multiple myeloma

Published:2019-10-07 Issue:2 Volume:34 Page:578-588
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

An Gang,Yan Yuting,Xu Yan,Mao Xuehan,Liu Jiahui,Fan Huishou,Wang Qi,Du Chenxing,Li Zengjun,Yi Shuhua,Lv Rui,Deng Shuhui,Sui Weiwei,Fu Mingwei,Hao Mu,Huang Wenyang,Zou Dehui,Zhao Yaozhong,Yuan Chenglu,Du Xin,Wang Jianxiang,Cheng Tao^ORCID,Tai Yu-Tzu,Munshi Nikhil C.,Qiu Lugui

Funder

National Natural Science Foundation of China

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/s41375-019-0590-x.pdf

Reference32 articles.

1. Rawstron AC, Child JA, de Tute RM, Davies FE, Gregory WM, Bell SE, et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol. 2013;31:2540–7.

2. Paiva B, Gutierrez NC, Rosinol L, Vidriales MB, Montalban MA, Martinez-Lopez J, et al. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood. 2012;119:687–91.

3. Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328–e46.